

555
F819

EVALUATION OF THE
1954 FIELD TRIAL OF
POLIOMYELITIS VACCINE

FINAL REPORT

by

Thomas Francis, Jr., M.D.
John A. Napier
Robert B. Voight, B.S.
Fay M. Hemphill, Ph.D.
Herbert A. Wenner, M.D.
Robert F. Korns, M.D.
Morton Boisen, B.A.
Eva Tolchinsky
Earl L. Diamond, M.A.

POLIOMYELITIS VACCINE EVALUATION CENTER
DEPARTMENT OF EPIDEMIOLOGY, SCHOOL OF PUBLIC HEALTH
UNIVERSITY OF MICHIGAN, ANN ARBOR, MICHIGAN
APRIL, 1957

sponsored by

THE NATIONAL FOUNDATION FOR INFANTILE PARALYSIS

MEDICAL LIBRARY,
MCGILL UNIVERSITY,
MONTREAL, Canada

EVALUATION OF THE
1954 FIELD TRIAL OF
POLIOMYELITIS VACCINE

FINAL REPORT

LIBRARY OF CONGRESS CATALOG CARD NUMBER: 57-10831

Lithoprinted in U.S.A.
EDWARDS BROTHERS, INC.
Ann Arbor, Michigan

ORGANIZATION OF THE POLIOMYELITIS VACCINE EVALUATION CENTER
FOR THE 1954 FIELD TRIAL

Thomas Francis, Jr.	Director	
Robert F. Korns	Deputy Director	
Robert B. Voight	Fay M. Hemphill	
Chief of Statistical Operations	Statistician, Technical Advisor	
Morton Boisen	Eva Tolchinsky	
Ass't. Chief of Statistical Operations	Tabulations Assistant	
John A. Napier	Margaret M. Johnson	
Supervisor, Statistical Procedures	Administrative Secretary	
Herbert A. Wenner	Laboratory Liaison	
Technical Assistants on loan from the Communicable Disease Center:		
Richard H. Seibert	Earl L. Diamond	James J. Tumbusch

ORGANIZATION OF THE POLIOMYELITIS VACCINE EVALUATION CENTER
FOR PREPARATION OF THE FINAL REPORT

Thomas Francis, Jr.	Director
John A. Napier	Manager of Publication
Cynthia K. Rollings	Margaret F. Craig
Table Preparation	Manuscript Editing
Elizabeth Barbo	Joseph G. Williams
Manuscript Typing	Drafting and Artwork
Robert B. Voight	Operations Consultant
Fay M. Hemphill	Statistical Advisor
Herbert A. Wenner	Laboratory Consultant
Earl L. Diamond	Statistical Consultant

ACKNOWLEDGMENTS

The Staff of the Vaccine Evaluation Center was a remarkable group. Dr. Korn, on leave from his position as Epidemiologist of the New York State Department of Health, served as Deputy Director. His acquaintance with field studies and with a great proportion of the health officers, made for ready and friendly understanding. With his extensive knowledge of poliomyelitis and of epidemiology, together with his energy and great ability, he was of invaluable assistance to all phases of the Evaluation Program.

Mr. Voight, and his associates, Mr. Boisen, Miss Tolchinsky, and Mr. Napier, took charge of the statistical operations. They had a long experience working together in the handling and analysis of masses of records. Their great competence, high standards of performance and willing acceptance of responsibility, individually and as a unit, made that phase of the evaluation a smooth-working operation. This expert group joined the staff on leave from the U. S. Bureau of the Census to which our thanks is extended. It was a fortunate acquisition arranged through the good offices of Professor Rensis Likert and Professor Angus Campbell of the Institute for Social Research.

Dr. Hemphill, in addition to his academic duties, gave generous and expert help to the Evaluation Center, especially in statistical appraisals of significance and effects. His studies included extensive computations of laboratory data and measurement of antigenic effect. He also prepared the chapter on Statistical Methods. In all this work he had the able, interested assistance of Mr. Earl Diamond.

Dr. Herbert Wenner, of the University of Kansas Medical School, undertook a responsible task in helping to establish and maintain uniformity of procedure among laboratories. He also provided great assistance in the preparation of the chapter on Laboratory Procedures for the Final Report.

It should be mentioned that the Final Report has been prepared by a small staff most of whom had not previously been intimately familiar with the studies. Mr. Napier has remained with the Center and has served reliably and effectively as the manager of the Center and of the Final Report. Miss Elizabeth Barbo did most of the typing of the Summary Report and also the Final Report. Mrs. Margaret Craig has served with great competence as the editorial assistant responsible for detailed problems of editing and assembling the Final Report. Miss Margaret Johnson, who served as administrative secretary earlier, has loaned her efficient services in the final assembly of this report. The cover was designed by Mr. Joseph Williams who also served as draftsman for charts, tables, and headings.

The chapters on organization and procedure of the Field Trial were prepared primarily by Mr. Voight and Mr. Boisen prior to their return to the Bureau of the Census. Mr. Voight has, when possible, continued to assist in reviewing and revising sections of the report. Dr. Calvin Kunin, Epidemiological Intelligence Officer, aided for a time in analyses related to provocation and inapparent infection. Certain chapters have been largely assembled by other members of the staff. However, the major load of continued review, analysis and appraisal, as well as writing

ACKNOWLEDGMENTS

and rewriting, with Mr. Napier's help, has been carried out by the Director and for this he accepts full responsibility.

Sincere acknowledgment is made again to the health authorities, the practicing physicians, the school authorities and all those who bore the brunt of work and responsibility in the study areas. Their continued attention to the requirements of this investigation in addition to their normal duties was an outstanding contribution. It is probable that the education and experience gained from their activities in the Field Trial will add to their knowledge and interest in studies of a similar nature on a national scale.

The collaborative investigations of the virologists provided fundamental data as to the antigenicity of vaccine and to the accurate diagnosis of reported cases. Only their excellence made this phase of the work possible.

The physical therapists, too, made essential contributions to diagnosis and evaluation by their skilled examinations of patients.

There is deep appreciation of the wise professional help and support given so freely and so proficiently by those who served as the Advisory Committee to the Evaluation Center. They aided consistently in consideration of matters of policy and of intricate technical problems. Although only one meeting of the Committee has been held since the Summary Report, many of them, individually, have continued to advise and assist with problems considered in the Final Report.

A debt of gratitude is expressed to colleagues in the Department of Epidemiology and to Dr. Henry F. Vaughn, Dean of the School of Public Health, for their strong support and forbearance during the extended period of this activity.

Sincere appreciation is also expressed to the University of Michigan for lending its great prestige and ready assistance in support of the Vaccine Evaluation Center. The ample facilities and special services which it has provided were important assets to efficient functioning of the Program.

The National Foundation for Infantile Paralysis provided to the University of Michigan the funds for the Vaccine Evaluation Program. This support has been extended to the additional studies which have been necessary in the preparation for the Final Report. The spirit of understanding has also continued. Dr. Van Riper, Medical Director of the Field Trial, and all his associates have freely provided any assistance which could be helpful. To Mr. Basil O'Connor we express our gratitude for his staunch, unwavering support of the principles established for the study. His broad perspective and courageous judgment were essential influences in the creation and conduct of both the Field Trial and the Evaluation Program.

Finally, we wish to express our admiration and indebtedness to the American Public whose contributions and participation made these investigations possible. The future will owe much to their exemplary deeds.

— T. F.

TABLE OF CONTENTS

chapter		page
I	SUMMARY OF RESULTS AND CONCLUSIONS	1
	The Study Population	2
	Incidence During the Study Period	2
	Prevalence by Diagnostic Class	2 ✓
	Distribution of Study Cases by Diagnostic Class and Vaccination Status	5 ✓
	Laboratory-Positive Cases	8
	Virus-Positive Cases	15
	Estimates of Effectiveness of Vaccine	15
	Factors Affecting the Results	19 ✓
	Nature of Cases in the Vaccinated	19 ✓
	Question of Provocation	20 ✓
	Antigenic Potency and Effectiveness	20 ✓
	Age	21 ✓
	Orphan Virus Infections	21
II	ORGANIZATION OF THE 1954 FIELD TRIAL	24
	Background and Perspectives	24
	Scope of Study	26
	Factors Determining Scope	26
	Geographic Requirements	26
	Age Factors	27
	Number of Children Required for Study	28
	Other Factors	29
	Selection of Field Trial Areas	29
	Plans of Study	30
	The Observed Control Plan	31
	The Placebo Control Plan	31
	Provision for Thorough Reporting of Data	32
	Socio-Economic Characteristics, Participants and Nonparticipants	32
	Division of Responsibility	35
	Standardization of Procedures	36
	Timetable and Schedule of Inoculations	36
III	CONDUCT OF THE FIELD TRIAL	39
	Registration of the Study Population	39
	Registration Schedule	39
	Participation Request	39
	Vaccination Record	40
	Adequacy of Registration	40
	Demographic Characteristics of the Study Population	48
	Administration of Vaccine	49
	Organization of Vaccine Clinics	49
	Vaccine-Placebo Code Scheme	51
	Labeling and Packaging	52
	Vaccine Codes in Observed Control Study Areas	54
	Clinic Procedures	55
	Make-Up Clinics	56
	Supplemental Supplies of Vaccine and Placebo	56

TABLE OF CONTENTS

chapter		page
III contd	Atmosphere of Clinics and Awards to Participants	57
	Completeness of Vaccination and Matching of Controls	58
	Comparability of the Test Populations	59
	Procurement of Blood Samples	61
	VEC Staff Supervision	63
	Observation of Clinics	63
	Meetings with State and Local Authorities	64
	Communication with Field Trial Areas	65
IV	RECEIPT AND PROCESSING OF BASIC RECORDS	68
	Processing and Tabulation	69
	Receipt, Check-In and Control Procedures	69
	Editing and Coding	69
	Detection of Recording Errors Made in Field Clinics	71
	Vaccine and Placebo Recodes	71
	Methods Used to Correct Errors and Omissions	71
	Quality Control and Error Detection	72
	Punching of Basic Data Cards	74
	Tabulation of Basic Population Data	74
V	REPORTING AND INVESTIGATION OF CASES IN THE STUDY POPULATION	76 ✓
	Reporting of Cases	77
	Investigation of Reported Cases	78
	Clinical - Epidemiological Investigation	78
	Laboratory Specimens	79
	Examination by Physical Therapist	79
	Fatal Cases	82
	Steps Taken to Ensure Completeness of Investigation	82
	Follow-Up of Persons Who Moved During the Study Period	83
	Procedure for Tabulation of Case Data	84
VI	FORMULATION OF DIAGNOSTIC CRITERIA FOR CLASSIFICATION OF CASES.	86 ✓
	Definition of Paralytic Status and Severity	86
	Minimal Criteria for Classification of a Reported Case as Paralytic.	87
	Grading of Spinal Paralysis by Severity	87
	Interpretation of Laboratory Investigation of Cases.	89
	Virus Isolation	90
	Relation of Virus Recovery to Serological Response	90
	Relation of Virus Recovery to Date of Stool Collection	91
	Serological Tests	92
	Number of Tests	94
	Significance of Rises in Antibody	94
	Interpretation of Homologous Antibody Only	97
	Relation of Titers to Time of Collection of Blood	100
	Relation Between Homologous and Heterologous Antibody	102
	Serological Interpretation	105
	Changes in Heterologous Titers	107
	Criteria for Interpretation of Viral and Serological Results	108
	Classification of Virus Tests	108
	Interpretation of Serological Results	109
	Final Diagnostic Classification	110
	Paralytic Poliomyelitis	110
	Nonparalytic Poliomyelitis	110
	Doubtful Poliomyelitis	111
	Fatal Cases	111
	Not Poliomyelitis	111
	Distribution of Cases by Diagnostic Class	111

TABLE OF CONTENTS

chapter

page

VII

	LABORATORY PROCEDURES AND APPRAISAL OF LABORATORY RESULTS . . .	113
	Objectives of the Laboratory Program	113
	Measurement of Antibody Response to Vaccine	113
	Investigation of Cases	115
	Participating Laboratories	115
	Procedures Used by Participating Laboratories	116
	Tissue Culture Systems	116
	Types of Tissue Culture Systems Employed	116
	Standard Viruses	117
	Standard Sera	118
	Media Available to Participating Laboratories	118
	Antibody Assay and Virus Detection	118
	Tests for Neutralizing Antibodies	118
	Pre- and Post-Vaccination Sera	118
	Sera from Reported Poliomyelitis Cases and Contacts	119
	Standards for Determining Antibody Endpoints	120
	Detection of Virus	120
	Stool Specimens	120
	Post-mortem Tissues	120
	Method of Typing Poliomyelitis Viruses	120
	Factors Related to Assessment of Laboratory Results	121
	Standard Virus Pools	122
	Stability	122
	Potency	122
	Standard Reference Sera	123
	Human Reference Sera	124
	Dilution of Test Sera	124
	Toxic Sera	125
	Effective Cell Mass	125
	Dilutions of Reagents	126
	Incubation of Serum-Virus Mixtures	126
	Reading the Colorimetric Endpoints	126
	Appraisal of Laboratory Results	127
	Titration of Standard Reference Sera and Virus Preparations	127
	Titration of Exchanged Sera	134
	Variations Between Four-tube and One-tube Tests	134
	Variations in Antibody Titer of Serum Pools	134
	Variations in Titers of "Unknown" Sera	135
	Variations in Titers of Human Sera	135
	Variations in Titers Before and After Primary and Secondary Vaccination	138
	Variations in Titers of Identical Sera Tested by Three Laboratories	139
	Variations Measured by Compiled Results of Field Studies	141
	Variations in Titer Between First and Second Sera of	
	Controls - Total	141
	Variations in Toxicity and Titers of Controls - by Laboratory	141
	Variations in Titers of Children from Different Areas	
	Vaccinated with the Same Lots of Vaccine	144
	Laboratory Consistency as Measured by Determination of	
	Heterologous Antibody in Patients	144
	Reliability of Tests for Detection of Poliomyelitis Virus	147
	Limitations of Tissue Culture Systems	147
	Observations on Cytopathogenic Agents Not Identified	148
	Complement-Fixation Tests in Diagnosis of Poliomyelitis	148
	Summary	148

VIII

	MEASUREMENT OF ANTIGENIC POTENCY OF VACCINE AND STABILITY OF	
	ANTIBODY TITERS	150
	Measurement of Antigenic Potency of Vaccine	150
	The Serological Material Used	151

TABLE OF CONTENTS

chapter		page
VIII	Antibody Status Prior to Vaccination Clinics	152
	Response to Vaccine	155
contd	Variation in Response to Lots of Vaccine	156
	Conversion of Triple Negatives to Triple Positives	157
	Response in Children Without Antibody to Any Type Before Vaccination	157
	Response According to Original Antibody Pattern	158
	Comparability in Controls	159
	Response in Relation to Initial Level of Antibody	160
	Response in Children With No Antibody to a Given Type	161
	Relative Antigenic Effect of Different Vaccine Lots	163
	Relation of Antigenic Potency to Prophylactic Effectiveness	164
	Relationship of "Expected" to "Actual" Cases in Vaccinated Children	172
Stability	of Antibody Titers	177
	Relation of Antibody Stability to Lots of Vaccine	177
	Inapparent Infection	187
	Increases in Titer Among Controls Without Type-Specific Antibody	
	Initially	190
	Changes in Titer Among Controls Without Reported Antibody to any	
	Type Initially	190
	Relation of Titer Changes in Controls to Occurrence of Type-Specific	
	Cases in Specific Areas	193
	Titers of Paired Early and Late Post-Vaccination Sera	195
	Stability of Titers in Persons Without Antibody to Any Type Previous to	
	Vaccination	199
	Antibody Titers Obtained in Simultaneous Tests of First, Second, and	
	Third Bloods	202
	Stability by Lots as Measured in the Three Simultaneous Tests	210
	Antibody Levels One Year Later and Response to "Booster" Vaccine	213
IX	INCIDENCE OF REPORTED POLIOMYELITIS IN 1954	223
	Incidence Ages Six to Nine	223
	Incidence in Study Population	226
X	STUDY OF POSSIBLE REACTIONS, PROVOCATION, AND DEATHS IN	
	THE STUDY POPULATION	230
	Study of Possible Reactions to Vaccination	230
	Pittsburgh Studies of Reactions and Absenteeism	230
	First Pittsburgh Study	230
	Extended Studies in Pittsburgh Schools	233
	New York Studies of Reactions and Absenteeism	237
	Schenectady Study	237
	Nassau County and New York City Studies	238
	Reactions as Recorded During the Field Trial	238
	Search for Other Illnesses Possibly Related to Vaccination	241
Study of	Possible Provocation	242
	Poliomyelitis Cases Reported During Vaccination Period	243
	Early Cases in Texas	243
	Cases in Familial Associates of Vaccinated Children	244
	Vaccine Lots Associated with Early Cases	244
	Incidence in Controls and Nonparticipants of Placebo Areas	245
	Total Cases by Week of Onset	246
	Influence of Nonparticipants upon Rates in Observed Controls	249
	Localization and Severity of Paralysis in Relation to Inoculation Status	251
	Summary	255
Review	of Deaths in the Study Population	255
	Specific Causes of Deaths in Placebo Areas	256
	Specific Causes of Deaths in Observed Areas	257

TABLE OF CONTENTS

chapter		page
XI	EXTENT AND LOCATION OF PARALYSIS	258
	Extent of Paralysis	258
	Location of Paralysis	259
	Muscular Impairment at First and Second Examinations	261
	Relation of Vaccination to Changes in Impairment Between Examinations	263
	Comparison of Paralytic Involvement in Placebo and Observed Areas	264
	Frequency and Severity of Involvement of Specific Muscles	266
	Summary	268
XII	DISTRIBUTION OF POLIOMYELITIS CASES BY AGE, SEX, AND COLOR	270
	Distribution of Poliomyelitis Cases by Age	271
	Vaccine Effectiveness for Specific Age Groups	272
	Recording of Age	276
	Serological Data	277
	Antibody Response to High Potency Lots	278
	Response to Lots of Lesser Potency	279
	Paralytic Cases by Vaccine Lots	279
	Antibody Response in Children Under Six Years of Age	280
	Decline in Post-Vaccination Antibody Titers	280
	Nature of Cases in Vaccinated Six-Year-Olds	281
	Virus Isolation and Serology	281
	Muscular Impairment	282
	Relation of Orphan Viruses to Incidence in Six-Year-Olds	283
	Incidence by Age - Observed Areas	289
	Summary	290
	Distribution of Poliomyelitis Cases by Sex	292
	Distribution of Poliomyelitis Cases by Color	294
XIII	CASES WITH LABORATORY EVIDENCE OF "ORPHAN" VIRUS	296
	Clinical Symptoms	296
	Muscular Involvement	296
	Serological Findings	299
	Age Distribution	301
	Distribution by Sex	302
	Temporal Distribution	302
	Summary	304
XIV	FURTHER STUDY OF PARALYTIC CASES AMONG THE VACCINATED GROUP AND CASES WITH PRE-ILLNESS SEROLOGY	305
	Serology and Virus Isolation	305
	Muscular Impairment	310
	Chronology of Virus Positive Paralytic Cases	311
	Summary	311
	Cases with Pre-Illness Serology	313
XV	CASES AMONG FAMILIAL ASSOCIATES OF STUDY CHILDREN	315
	Secondary Attack Rates	315
	Subclinical Infection	316
	Family Studies	316
	Virus Recovery from Non-Study Cases	317
	Virus Recovery from Study Members	317
	Virus Recovery from Non-Study Familial Associates of Cases	318
	Antibody Patterns of Persons Exposed to Poliomyelitis Virus	319
	Reported Cases in Familial Associates	323
	Paralytic Status of Index and Subsequent Cases	324
	Relation of Family Size to Occurrence of Poliomyelitis	324
	Summary	326

TABLE OF CONTENTS

chapter		page
XVI	FIELD TRIALS IN CANADA AND FINLAND	327
	Potency of Vaccine Used in Canada and Finland	328
	Occurrence of Poliomyelitis in Study Groups	328
XVII	STATISTICAL METHODS USED IN THE EVALUATION OF THE POLIOMYELITIS VACCINE	332
	Rates	333
	Estimate of Effectiveness	333
	Tests for Significance and Confidence Limits	333
	Probability Distribution of Cases	334
	Tests of Significance	335
	Confidence Limits	335
	Another Approach to Statistical Evaluation	336
	Tests and Confidence Limits When Sizes of Vaccinated and Control Groups are Equal	336
	Tests and Confidence Limits When Sizes of Vaccinated and Control Groups are Unequal	337
	Comparing the Sampling Survey Method and the Poisson Distribution Method	338
	Estimates of Population Characteristics	338
	Chi-Square	338
	Analysis of Variance	339
	Geometric Means	339
APPENDICES		
A	343
	Open Letter from Dr. Thomas M. Rivers to the Medical Profession, February 4, 1954.	344
	Advisory Committee, Poliomyelitis Vaccine Evaluation Center	345
	State and Local Health Officials Participating in the 1954 Poliomyelitis Vaccine Field Trial	346
	Laboratories Participating in the 1954 Poliomyelitis Vaccine Field Trial	349
	Physical Therapists Participating in the 1954 Poliomyelitis Vaccine Field Trial	352
	Epidemiological Intelligence Officers Assigned to Assist State Health Departments and Participating Laboratories During the 1954 Field Trial	352
B	353
	Detailed Statistics for Individual Field Trial Areas	353
C	393
	VEC Memoranda	394
	N. F. I. P Memorandum of October 8, 1954 - Third Bleedings	409
D	413
	Form Letters to State and Local Health Officials	414
	Form Letters to Participating Laboratories	445
E	456
	Outline of Basic Records Processing by the Vaccine Evaluation Center	458
	Outline of Case Records Processing by the Vaccine Evaluation Center	459
	Basic Field Reporting Forms	460
	VEC Processing and Administrative Forms and Procedures	469
F	541
	Abstract of Child Health Study	542
GLOSSARY		557
BIBLIOGRAPHY		561

LIST OF FIGURES

chapter	figure number	page
I	1. Trend of Paralytic Poliomyelitis Cases Among Vaccinated Children and Their Control Groups - Placebo and Observed Areas	18
II	2. Reported Poliomyelitis Cases per 100,000 Population for the United States, 1915-1954	27
	3. Poliomyelitis Age-Specific Acute Admission Rates per 100,000 Population - 1952, 1953, 1954	28
VI	4. Acute by Convalescent Titers by Days Elapsed from Onset to Collection of Acute Specimen, Virus-Positive Paralytic and Nonparalytic Cases - Placebo and Observed Areas Combined	98
	5. Acute and Convalescent Serology of All Paralytic and Nonparalytic Cases	106
VII	6. Antibody Studies in Three Participating Laboratories with Three Lines of Type III (Saukett) Virus	123
	7. Average and Standard Deviation of Control Titers by Laboratory - Type III Standard Monkey Serum	131
	8. Average and Standard Deviation of Control Titers by Laboratory - Type I High Human Serum	132
	9. Average and Standard Deviation of Control Titers by Laboratory - Type II Low Human Serum	133
	10. Serum Antibody Obtained with "Unknown" Sera by Different Laboratories	135
VIII	11. Virus-Positive Poliomyelitis Cases by Vaccine Lot and Virus Type	176
	12. Virus-Positive Poliomyelitis Cases by Virus Type - Placebo and Observed Areas	176
	13. Initial Response vs. Return to Negative Antibody Status - Type I	220
	14. Initial Response vs. Return to Negative Antibody Status - Type II	221
	15. Initial Response vs. Return to Negative Antibody Status - Type III	222
IX	16. Number of Reported Poliomyelitis Cases in the Vaccine Field Trial Areas by Specific Age Groups - 1952, 1953, and 1954	228
X	17. Cumulative Rates per 100,000 by Weeks from First Inoculation to Date of Onset - Paralytic Cases, Placebo Areas	248
	18. Cumulative Rates per 100,000 by Weeks from First Inoculation to Date of Onset - Paralytic Cases, Observed Areas	249
	19. Cumulative Rates per 100,000 by Weeks from First Inoculation to Date of Onset - Paralytic Cases Among Placebo and Not Inoculated Children Combined and for Complete and Partial Vaccinees Combined - Placebo Areas	252
	20. Cumulative Rates per 100,000 by Weeks from First Inoculation to Date of Onset - Paralytic Cases Among Controls and 2nd Grade Not-Inoculated Combined and for Complete and Partial Vaccinees Combined - Observed Areas	253
XII	21. Probability of "6-Year-Old Result" or One Less Favorable to the Vaccine, for Varying Values of True Effectiveness	275
	22. Composite Results of Antibody Response With Lot 309, Three Virus Types - Ages 1-5 and 6-9	286

LIST OF TABLES

chapter	table number	page
I	1. Participation Status of Study Population by Vaccination Status - Placebo Areas	2
	2. Participation Status of Study Population by Vaccination Status - Observed Areas	3
	3. Study Cases by Diagnostic Class - Placebo and Observed Areas	3
	4. Field Diagnosis (FT-6) Compared with VEC Diagnosis Placebo and Observed Areas	4
	5. Diagnostic Class by Vaccination Status of Study Cases - Placebo and Observed Areas	5
	6. Degree of Paralysis by Diagnostic Category and Vaccination Status of Study Cases - Placebo Areas	6
	7. Degree of Paralysis by Diagnostic Category and Vaccination Status of Study Cases - Observed Areas	7
	8. Virus Isolation by Serology and Vaccination Status - Poliomyelitis Study Cases, Placebo and Observed Areas	8
	9. Poliomyelitis Virus Isolations from Case Specimens Tested for Study Cases, by Diagnostic Category - Placebo and Observed Areas	11
	10. Laboratory Positive Study Cases by Degree of Paralysis, Diagnostic Category, and Vaccination Status - Placebo Areas	12
	11. Laboratory Positive Study Cases by Degree of Paralysis, Diagnostic Category, and Vaccination Status - Observed Areas	13
	12. Virus-Positive Paralytic and Nonparalytic Poliomyelitis Study Cases by Type of of Virus Isolation and Vaccination Status - Placebo and Observed Areas	14
	13. Estimates of Effectiveness of Vaccine at Successive Stages of Analysis - Placebo and Observed Areas	16
	14. Degree of Paralysis by Diagnostic Category and Vaccination Status of Study Cases (Excluding Orphan Virus Cases) - Placebo Areas	22
	15. Degree of Paralysis by Diagnostic Category and Vaccination Status of Study Cases (Excluding Orphan Virus Cases) - Observed Areas	23
II	16. Poliomyelitis Crude Case Rates by Size of County, 1948-1952	29
	17. Summary of Socio-Economic Characteristics	34
III	18. Participation Status and Vaccination Status by Field Trial Area - Placebo Areas	41
	19. Participation Status and Vaccination Status by Field Trial Area - Observed Areas	44
	20. School Grade by Participation Status - Placebo and Observed Areas	48
	21. Distribution of Study Population by Community Size and by Color - Placebo and Observed Areas	49
	22. Participation Status of Study Population by Vaccination Status - Placebo Areas	57
	23. Participation Status of Study Population by Vaccination Status - Observed Areas	59
	24. Vaccination Status, Sex and Age of Study Population - Placebo and Observed Areas	60
	25. Blood Specimens Drawn (First, Second, and Third Bleedings) by Vaccination Status - Placebo and Observed Areas	62
IV	26. Processing Status of Basic Records Through All Stages of Operation (July 3, 1954 - February 20, 1955)	70
V	No Tables	
VI	27. Virus Isolation by Diagnostic Category and Serology for Study Cases - Placebo and Observed Areas	91
	28. Results of Tests for Virus in Stool by Number of Days Between Onset and Collection of Specimen and by Diagnostic Class - Placebo and Observed Areas Combined	93

LIST OF TABLES

chapter	table number	page	
VI contd	29. Homologous and Heterologous Antibody Content of Sera by Four-Fold Rises to Homologous Type, Virus-Positive Poliomyelitis Study Cases by Type of Virus Isolated - Placebo and Observed Areas Combined	95	
	30. Geometric Means of Acute and Convalescent Titers for Virus - Positive Paralytic Cases - Placebo and Observed Areas Combined	101	
	31. All Reported Study Cases With Virus Isolation and 4-Fold or Greater Rise to the Homologous Virus Type, by Titer Level of First Serum - Placebo and Observed Areas	102	
	32. Antibody Levels of Paired Sera of Paralytic Cases - Placebo and Observed Areas	103	
	33. Occurrence of Homologous and Heterologous Antibody in First of Paired Sera From Virus-Positive Paralytic Cases	104	
VII	34. Summary of Serological and Virological Tests Completed by Laboratories Participating in the Field Trial	114	
	35. The Potency and Stability of the Standard Virus Pools - Connaught Laboratories	117	
	36. Stability and Potency of the Standard Viruses Within Nine Participating Laboratories	121	
	37. Variations Noted in Pools of Saukett (Type III Virus)	122	
	38. Serum Dilution Endpoints of the Standard Reference Sera - Five Different Testing Methods	124	
	39. Serum Dilution Endpoints of Type I (Brunhilde) Reference Monkey Serum by Diluent and by Length of Storage Time and Temperature of Storage	125	
	40. Estimates of Dilution Error Using The Cornwall Automatic and the Standard Pipettes	126	
	41. Means (Averages) and Standard Deviations of Laboratory Reports on Virus Titer, Tissue Culture Dose and Standard Monkey Serum Titer - All Participating Laboratories	128	
	42. Means (Averages) and Standard Deviations of Laboratory Reports on High Human Serum Titer, Low Human Serum Titer and Log ₂ Human Sera Difference - All Participating Laboratories	129	
	43. Observed Variations in Serum Titers With the Same Sera in Two Participating Laboratories	134	
	44. Observed Variations in Serum Titers With Aliquots of the same Sera Tested in Ten Participating Laboratories	136	
	45. Variations in Titers of Sera Exchanged Between Laboratories	137	
	46. Results Obtained by Two Laboratories in Tests of Identical Sera, Pre- and Post-Primary and Pre- and Post-Secondary Vaccination Sera	138	
	47. Identical Sera Reported "Toxic" by One Laboratory and as Less Than 4 by Two Other Laboratories	139	
	48. Antibody Titers by Virus Type-Identical Sera Tested by Three Laboratories	140	
	49. Second Serum Titers of Unvaccinated (Control) Children With No Original Type - Specific Antibody in the First Serum, by Laboratory	142	
	50. Percentage of Agreement Between Titers of First and Second Sera of Unvaccinated Children, by Laboratory	143	
	51. Second Serum Titers of Vaccinated Children With No Original Type-Specific Antibody, as Recorded by Different Laboratories for the Same Vaccine Lots	145	
	52. Some Limitations of Tissue Culture Systems in the Detection of Poliomyelitis Virus in Stool Specimens	147	
	VIII	53. Pre- and Post-Vaccination Bloods Drawn, Tested, and Tabulated - Placebo and Observed Areas Combined	151
		54. Pre-Vaccination Antibody Levels by Virus Type - Placebo and Observed Areas Combined	152
		55. Pre-Vaccination Antibody Status by Vaccination Status - Placebo, Observed and Total Study Areas	154
		56. Children Reported Without Antibody to Any Virus Type in First Serum and With Antibody to All Three Types in Second Serum, by Vaccine Lot	156
		57. Pre-Vaccination Antibody Status by Post-Vaccination Antibody Status, by Virus Type and Vaccination Status - Placebo Areas	158
58. Pre-Vaccination Antibody Status by Post-Vaccination Antibody Status, by Virus Type and Vaccination Status - Observed Areas		159	

LIST OF TABLES

chapter	table number	page
VIII contd	59. Pre-Vaccination Serum Antibody Levels by Post-Vaccination Levels by Virus Type and Vaccination Status - Placebo Areas	160
	60. Pre-Vaccination Serum Antibody Levels by Post-Vaccination Levels by Virus Type and Vaccination Status - Observed Areas	161
	61. Vaccine Lots by Percent Relative Antigenic Effect to Each Poliomyelitis Virus Type	164
	62. Vaccine Lots Arranged by Relative Antigenic Effect to Each Poliomyelitis Virus Type	165
	63. Serum Antibody Titers for Paired Sera Where First Blood Titer Level is Less Than Four to Specified Type and to All Three Types, by Vaccine Lot, Virus Type and Vaccination Status - Placebo Areas	166
	64. Serum Antibody Titers for Paired Sera Where First Blood Titer Level is Less Than Four to Specified Type and to All Three Types, by Vaccine Lot, Virus Type and Vaccination Status - Observed Areas	167
	65. Serology and Clinical Data by Vaccination Status and Vaccine Lot - Placebo Areas	169
	66. Serology and Clinical Data by Vaccination Status and Vaccine Lot - Observed Areas	170
	67. Expected and Actual Cases in Vaccinated Children, by Vaccine Lot and Virus Type - Placebo Areas	173
	68. Expected and Actual Cases in Vaccinated Children, by Vaccine Lot and Virus Type - Observed Areas	174
	69. Expected and Actual Cases in Vaccinated Children, by Virus Type - Placebo and Observed Areas	175
	70. Percent Distribution of Antibody Levels at First, Second and Third Bleedings by Vaccine Lot, Virus Type, and Vaccination Status - Placebo Areas	178
	71. Percent Distribution of Antibody Levels at First, Second and Third Bleedings by Vaccine Lot, Virus Type, and Vaccination Status - Observed Areas	181
	72. First by Second by Third Serum Titers of Vaccinated Children by Lot Groups According to Relative Antigenic Effect, by Virus Type - Placebo Area Lots	188
	73. First by Second by Third Serum Titers of Vaccinated Children by Lot Groups According to Relative Antigenic Effect, by Virus Type - Observed Area Lots	189
	74. Antibody Status in Second and Third Sera of Control Children Without Type-Specific Antibody in First Serum, by Virus Type - Placebo and Observed Areas	191
	75. Antibody Status in Second and Third Sera of Control Children Without Type-Specific Antibody in First Serum, by Virus Type - Placebo and Observed Areas	192
	76. Laboratory Classification of Reported Cases in Controls and Changes in Serum Titers of "Non-Case" Controls Between Second and Third Bleedings, by Virus Type - Selected Study Areas	194
	77. Antibody Levels in Second Serum by Antibody Levels in Third Serum, by Virus Type and Vaccination Status - Placebo Areas	196
	78. Antibody Levels in Second Serum by Antibody Levels in Third Serum, by Virus Type and Vaccination Status - Observed Areas	197
	79. Second by Third Serum Titers of Children With No Antibody to Any Type in First Serum, by Virus Type and Vaccination Status - Placebo Areas	200
	80. Second by Third Serum Titers of Children With No Antibody to Any Type in First Serum, by Virus Type and Vaccination Status - Observed Areas	201
	81. Percent Distribution of Antibody Titers in First, Second, and Third Sera Tested Simultaneously, by Vaccination Status and Virus Type - Placebo and Observed Areas	203
	82. Second by Third Serum Titers by Vaccination Status and Virus Type for Persons Whose First Serum Titers Were < 4, 4 & 8, 16, 64, 256, and 1024 - Placebo Areas	204
83. Second by Third Serum Titers by Vaccination Status and Virus Type for Persons Whose First Serum Titers Were < 4, 4 & 8, 16, 64, 256, and 1024 - Observed Areas	206	
84. First Sera < 4 to Specified Type With Reported Titers of 4 or > in Second Serum and < 4 in Third Serum, by Vaccination Status, Virus Type and Vaccine Lot- Placebo Areas	211	

LIST OF TABLES

chapter	table number	Page
VIII contd	85. First Sera <4 to Specified Type With Reported Titers of 4 or > in Second Serum and <4 in Third Serum, by Vaccination Status, Virus Type and Vaccine Lot - Observed Areas	212
	86. Percent Distribution <4 to Specified Type in First, Second and Third Sera Tested Simultaneously, by Lot and Vaccination Status - Placebo Areas	214
	87. Percent Distribution <4 to Specified Type in First, Second and Third Sera Tested Simultaneously, by Lot and Vaccination Status - Observed Areas	215
	88. Two-Weeks Post-Vaccination Titers by One Year Post-Vaccination Titers, by Virus Type - 100 Selected Children in Three Michigan Study Areas	217
	89. Pre-Booster Titers by Post-Booster Titers, by Virus Type - 100 Selected Study Children in Three Michigan Study Areas	218
	90. Second, Third, Fourth, and Fifth Serum Titers of 19 Michigan Children With No Antibody to Any Type Prior to Vaccination	219
IX	91. Total Reported Poliomyelitis Cases, 1949-53 Average and 1954, for the United States by Regions and States	224
	92. Incidence of Poliomyelitis, Field Trial and Non-Field Trial Areas, All Ages - 1949-1953 Average and 1954	225
	93. Poliomyelitis Cases Reported June 15 to December 31, 1952, 1953, and 1954 in 1954 Study Areas, by Age - For All Children Six Through Nine Years - Placebo and Observed Areas	226
	94. Poliomyelitis Morbidity Rates by Specific Years of Age and by Cohort Ages, Vaccine Field Trial Areas - May 1 to December 31, 1952, 1953 and 1954	227
	95. Age Distribution of Reported Poliomyelitis Cases in Six Through Nine Year - Old Children - Placebo and Observed Study Areas Combined	229
X	96. Duration of Absence During the Vaccination Clinic Period, by Week of Occurrence - Twenty Schools in Pittsburgh, Pennsylvania	231
	97. Cause of Absence During Vaccination Clinic Period, by Week of Occurrence - Twenty Schools in Pittsburgh, Pennsylvania	232
	98. Duration of Absence After Second Inoculation, by Week of Occurrence - Five Public Schools in Pittsburgh, Pennsylvania	233
	99. Duration of Absence After Second Inoculation, by Week of Occurrence - Nine Parochial Schools in Pittsburgh, Pennsylvania	234
	100. Cause of Absence After Second Inoculation, by Week of Occurrence - Five Public Schools in Pittsburgh, Pennsylvania	235
	101. Cause of Absence After Second Inoculation, by Week of Occurrence - Nine Parochial Schools in Pittsburgh, Pennsylvania	236
	102. Cause of Absence During Vaccination Clinic Period by Inoculation Status - Twenty-Four Schools in Schenectady, New York	237
	103. Number of Children Absent Because of Allergies, by Type of Allergy, Twenty-Four Schools in Schenectady, New York	238
	104. Possible Reactions Recorded on Vaccination Records of Inoculated Children - Placebo and Observed Areas	239
	105. Study Cases With Onset Within 63 Days From Date of First Inoculation, by Diagnostic Class, Vaccination Status and Virus Recovery - Placebo Areas	242
	106. Study Cases With Onset Within 63 Days From Date of First Inoculation, by Diagnostic Class, Vaccination Status and Virus Recovery - Observed Areas	243
107. Texas Study Cases With Onset Within 63 Days From Date of First Inoculation, by Diagnostic Class, Vaccination Status and Virus Recovery	244	
108. Paralytic Cases Occurring Within 63 Days From First Inoculation Clinic by Vaccine Lot and Vaccination Status - Placebo and Observed Areas	245	
109. Paralytic Poliomyelitis Study Cases by Week of Onset and Vaccination Status - Thirteen Eastern New York Study Areas Combined	246	
110. Weekly Increments and Cumulative Rates per 100,000, by Vaccination Status for Paralytic Study Cases - Placebo Areas	247	
111. Paralytic Poliomyelitis Cases in Study Children Who Were Not Vaccinated - Placebo and Observed Areas	250	

LIST OF TABLES

chapter	table number	page
X contd	112. Poliomyelitis Cases Occurring Within 63 Days of First Inoculation Clinic, by Location and Extent of Paralysis and Vaccination Status - Placebo and Observed Areas Combined	251
	113. Paralytic Poliomyelitis Cases With Deltoid-Triceps and Gluteus Medius Involvement of "Fair" or Worse, by Weeks Elapsed From First Inoculation Clinic to Onset of Case, by Vaccination Status - Placebo and Observed Areas Combined	254
	114. Deaths in Study Children Compared With 1952 Total Deaths in Children 6-9 Years of Age, by Cause of Death	256
	115. Six Fatalities With Involvement of the Kidney, Liver or Central Nervous System, by Cause of Death and Inoculation Status - Placebo Areas	256
	XI	116. Degree of Paralysis by Virus Isolation for Paralytic Spinal and Bulbo-Spinal Cases Combined and Virus Isolation for Nonparalytic Cases - Placebo and Observed Areas Combined
	117. Bilateral Paralysis of Grade II Through V Severity, by Major Anatomical Areas - Spinal and Bulbo-Spinal Cases, Placebo and Observed Areas	260
	118. Grade II-V Involvement in Major Anatomical Areas Cross-Classified by Grade II-V Involvement in Other Major Anatomical Areas - Virus-Positive Paralytic Spinal and Bulbo-Spinal Cases Combined, Placebo and Observed Areas Combined	261
	119. Number of Muscles Reported "Fair" or Worse at 50-70 Day Muscle Examination, by Major Anatomical Areas - Spinal and Bulbo-Spinal Cases With Grade II-V Involvement, Placebo and Observed Areas	262
	120. Degree of Paralysis at 10-20 Day Examination by Degree of Paralysis at 50-70 Day Examination - Paralytic Spinal and Bulbo-Spinal Cases Combined, Placebo and Observed Areas Combined	263
	121. Degree of Paralysis at 10-20 Day and 50-70 Day Examination, by Vaccination Status - Placebo and Observed Areas Combined	264
	122. Degree of Paralysis at 10-20 Day and 50-70 Day Examination by Vaccination Status Paralytic Spinal and Bulbo-Spinal - Placebo and Observed Areas	265
	123. Degree of Paralysis at 10-20 Day Examination by Degree of Paralysis at 50-70 Day Examination, by Vaccination Status - Paralytic Spinal and Bulbo-Spinal Cases, Placebo and Observed Areas	266
	124. Degree of Paralysis at 10-20 Day Examination by Degree of Paralysis at 50-70 Day Examination, by Vaccination Status - Paralytic Spinal and Bulbo-Spinal Cases (Excluding Orphan Virus Cases) - Placebo and Observed Areas	267
	125. Muscles Ranked According to Percentages Having Involvement of "Fair" or Worse, "Poor" or Worse, or "No Power" as Recorded for the 10-20 Day Muscle Examination - Placebo and Observed Areas	268
XII	126. Age as of May 1, 1954, and Sex, by Diagnostic Class and Vaccination Status - Total Reported Study Cases, Placebo Areas	272
	127. Paralytic and Nonparalytic Poliomyelitis Cases, by Age and Vaccination Status - Placebo Areas	273
	128. Observed (Actual) Paralytic Cases Versus Expected Paralytic Cases in Vaccinated and Placebo Children, by Age as of May 1, 1954 - (Muench Study) Placebo Areas	274
	129. Observed (Actual) Paralytic Cases Versus Expected Paralytic Cases in Vaccinated and Placebo Children, by Age as of May 1, 1954 - (Hemphill-Diamond Study) Placebo Areas	275
	130. Age as of May 1, 1954 by Diagnostic Category and Degree of Paralysis and by Vaccination Status - Total Reported Study Cases, Placebo Areas	276
	131. Paralytic Poliomyelitis Cases by Age as of August 31, 1954 - Placebo Areas	277
	132. Second Serum Antibody Status of Vaccinated and Placebo Children Who Had No Antibody to Any Virus Type in First Serum - Placebo Areas	278
	133. Pre- and Post-Vaccination Antibody Status by Vaccination Status and Age - Placebo Areas	279

LIST OF TABLES

chapter	table number	page
XII contd	134. Four-Fold or Greater Rise in Type-Specific Antibody - Lots 304, 306, and 512 Combined	280
	135. Antibody Response by Age and Virus Type - Vaccine Lot 304	281
	136. Antibody Response by Age and Virus Type - Vaccine Lots 304, 306 and 512 Combined	282
	137. Antibody Response by Age and Virus Type - Vaccine Lots 302 and 503 Combined	283
	138. Vaccine Lot by Age and Vaccination Status - All Paralytic Poliomyelitis Cases, Placebo Areas	284
	139. Paralytic Poliomyelitis Cases by Month of Onset, Vaccination Status, and Age as of May 1, 1954 - Placebo Areas	285
	140. Isolation of Virus From Six-Year-Olds - Paralytic Poliomyelitis Cases, Placebo Areas	286
	141. Acute and Convalescent Serum Titers of 4 Paralytic Cases in Six-Year-Old Vaccinated Children From Whom Type I Virus Was Recovered - Placebo Areas	287
	142. Muscle Scores of Orphan-Virus or No Virus Cases in Six-Year-Olds - Placebo Areas	287
	143. Placebo Poliomyelitis Cases With Poliomyelitis Virus and Orphan Virus Recovered, by Age as of May 1, 1954 - Placebo Areas	287
	144. Paralytic Study Cases by Diagnostic Category, Vaccination Status and Age (Excluding Cases From Whom an Orphan Virus Was Recovered)-Placebo Areas	288
	145. Laboratory Postive Paralytic Cases, Virus Postivie Paralytic Cases and All Orphan Virus Cases, by Age - Placebo Areas	289
	146. Laboratory Positive and Poliomyelitis Virus Positive Paralytic Cases by Virus Type, Vaccination Status, and Age as of May 1, 1954 - Placebo Areas	290
	147. Nonparalytic Cases by Virus Type, Vaccination Status and Age - Placebo Areas	291
	148. Age as of May 1, 1954, and Sex, by Diagnostic Class and Vaccination Status- Total Reported Study Cases, Observed Areas	292
	149. Percent Distribution of Pre-Inoculation Antibody Titers of Vaccinated and Placebo Children Combined, by Virus Type and Sex - Placebo Areas	293
	150. Post-Vaccination Antibody Levels for Vaccinated Children Without Type-Specific Antibody Prior to Vaccination, by Virus Type by Sex - Placebo Areas	294
	151. Reported Study Cases Among White and Nonwhite Study Members by Diagnostic Classification and Vaccination Status - Placebo and Observed Areas	295
XIII	152. Clinical Signs and Symptoms of Orphan Virus Cases	296
	153. Study Cases From Whom an Orphan Virus Was Isolated by VEC Diagnosis, Vaccination Status and Degree of Paralysis - Placebo and Observed Areas	297
	154. Degree of Paralysis at First and Second Muscle Examinations of Orphan Virus Cases VEC Diagnosed as Poliomyelitis	298
	155. Serological Results by VEC Diagnosis and Vaccination Status for Orphan Virus Cases - Placebo and Observed Areas	300
	156. Age as of May 1, 1954, by Diagnostic Classification and Vaccination Status for Orphan Virus Cases - Placebo and Observed Areas	301
	157. Incidence Rates by Age as of May 1, 1954, by Diagnostic Classification and Vaccination Status for Total Cases and Orphan Virus Cases - Placebo Areas	302
	158. Orphan Virus and Total Cases by Sex, Vaccination Status and Diagnostic Classification - Placebo and Observed Areas Combined	303
	159. Temporal Distribution of Orphan Virus Cases - Massachusetts and Central New York Combined	304
	XIV	160. Antibody Pattern of Acute Stage Serum, by Virus Isolation and Vaccination Status for Paralytic Poliomyelitis Cases - Placebo Areas
161. Antibody Pattern of Acute Stage Serum, by Virus Isolation and Vaccination Status for Paralytic Poliomyelitis Cases - Observed Areas		307

LIST OF TABLES

chapter	table number	page
XIV contd	162. Laboratory Positive Poliomyelitis Study Cases Versus Cases Not Laboratory Positive, by Diagnostic Category and Vaccination Status- Placebo Areas	309
	163. Virus-Negative Paralytic Poliomyelitis Cases in the Vaccinated Study Population Arranged According to 10-20 Day Muscle Score - Placebo and Observed Areas	310
	164. Virus-Positive Paralytic Poliomyelitis Cases in the Vaccinated Study Population Arranged According to 10-20 Day Muscle Score- Placebo and Observed Areas	311
	165. Virus-Positive Paralytic Cases by Month of Onset and Vaccination Status- Placebo and Observed Areas	312
	166. Summary Listing of Data for Cases in Children With Pre-Illness Serological Examinations, by Vaccination Status - Placebo and Observed Areas Combined	314
	XV	167. Exposure Rates and Secondary Attack Rates by VEC Diagnosis, Vaccination Status, and Virus Isolation-Placebo and Observed Areas
168. Virus Isolation From Non-Study Member Cases by Virus Type and Vaccination Status of Study Member - Placebo and Observed Areas Combined		317
169. Recovery of Virus From Study Members Who Were Exposed to a Reported Case of Poliomyelitis in the Family, by Vaccination Status and Virus Type - Placebo and Observed Areas Combined		318
170. Recovery of Virus From Non-Study Familial Associates of Cases - Placebo and Observed Areas Combined		319
171. First and Second Serum Antibody Levels by Virus Type, of Persons Exposed to a Laboratory Confirmed Case of Poliomyelitis in the Family - Placebo and Observed Areas Combined		320
172. First by Second Serum Antibody Levels of Vaccinated Study Members Exposed to Type I or Type III Virus - Placebo and Observed Areas Combined		321
173. First by Second Serum Antibody Levels of Placebo and Not Inoculated Study Members Exposed to Type I or Type III Virus - Placebo and Observed Areas Combined		322
174. Reported Poliomyelitis Cases in Family Associates, by Vaccination Status of Study Member - Placebo Areas		323
175. Reported Poliomyelitis Cases in Family Associates, by Vaccination Status of Study Member - Observed Areas		324
176. Paralytic Status of Index Case in Relation to Paralytic Status of Subsequent Cases in the Household - Placebo and Observed Areas Combined		325
177. Occurrence of Paralytic Study Cases by Size of Household Compared to the Size of Household as Determined from the Child Health Survey - Placebo Areas		325
XVI	178. Pre-Vaccination Titers by Post-Vaccination Titers - Vaccinated Children, Canada and Finland Combined	329
	179. Reported Poliomyelitis Study Cases by Diagnostic Class and Vaccination Status - Canada and Finland	330
XVII	180. Vaccination Status of Study Population as Determined From the Total Tabulation and From the Sample Tabulation - Placebo and Observed Areas	339